Nanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis

Area of Science:

• Hepatology and Gastroenterology
• Nanomedicine and Drug Delivery
• Molecular Biology and Signaling Pathways

Background:

• Hepatic fibrosis, a precursor to cirrhosis and cancer, involves activated hepatic stellate cells (HSCs) and excessive extracellular matrix (ECM) deposition.
• Key signaling pathways like TGF-β1, PDGF, NF-κB, Wnt/β-catenin, and JAK/STAT drive fibrosis progression and are critical therapeutic targets.

Purpose of the Study:

• To systematically review the roles of major signaling pathways in hepatic fibrosis.
• To examine the potential of nanotechnology-enhanced modalities for targeted delivery of therapeutic agents.
• To explore the integration of traditional Chinese medicine (TCM) with modern nanodelivery systems for improved fibrosis treatment.

Main Methods:

• Systematic review of literature on hepatic fibrosis signaling pathways.
• Analysis of nanotechnology-based drug, RNAi, and gene-editing tool delivery systems.
• Evaluation of TCM's multi-target regulatory potential and its challenges in clinical translation.

Main Results:

• Nanotechnology offers solutions for low bioavailability and off-target effects of conventional fibrosis agents.
• Targeted drugs show promise but face challenges in delivery efficiency, stability, and safety.
• TCM exhibits multi-target potential but requires standardization and mechanistic clarification for clinical use.

Conclusions:

• Integrating TCM with nanodelivery and precision medicine is crucial for advancing hepatic fibrosis treatment.
• Combinatorial nanomedicines designed for multi-pathway interference and precision delivery represent a paradigm shift.
• This approach could enable active fibrosis reversal and personalized treatment strategies for hepatic fibrosis.